# Decision Framework for Antiviral Therapy in Veterinary Patients


## Key Takeaways

- Antiviral therapy in veterinary medicine is characterized by a limited drug armamentarium and species-specific indications, necessitating a structured decision framework based on virus family, clinical syndrome, host immune status, and drug mechanism rather than a simple drug list.
- The decision to initiate antiviral therapy requires confirmation of a viral etiology amenable to intervention, with diagnostic tools like PCR, antigen detection, cytology, and serology playing crucial roles, though serology alone is often insufficient for active infection diagnosis.
- Antiviral drugs function by targeting specific viral replication steps, such as genome replication (e.g., nucleoside analogues inhibiting viral DNA polymerase) or viral release (e.g., neuraminidase inhibitors), and their efficacy is dictated by matching the drug's mechanism to the virus's replication strategy.
- Host factors significantly modify drug choice, including immune competence (influencing duration and resistance risk), renal and hepatic function (affecting drug clearance and toxicity), and pregnancy status (due to potential teratogenicity).
- Extrapolation from human medicine is common, but species-specific pharmacokinetics, such as poor oral acyclovir metabolism in cats, necessitate careful consideration, with famciclovir often being the preferred oral nucleoside analogue.
- Production animal antiviral therapy is further constrained by withdrawal periods, trade implications, and biosecurity protocols, often leading to depopulation strategies over treatment for highly contagious or zoonotic pathogens.

---

Antiviral therapy in veterinary medicine occupies a narrower therapeutic corridor than antibacterial therapy. The drug armamentarium is smaller, the indications are more species-specific, and the margin between efficacy and toxicity is often tighter. This article provides a structured decision framework for selecting antiviral therapy in dogs, cats, horses, and production animals, organized around virus family, clinical syndrome, host immune status, and drug mechanism. It is written for veterinary students and practitioners who need a reproducible reasoning pathway instead of a memorized drug list.

The framework answers three sequential questions. First, does the clinical presentation and diagnostic evidence support a viral etiology that is amenable to antiviral intervention? Second, which drug class matches the virus's replication strategy and the drug's tissue distribution? Third, what host factors modify drug choice, including immune competence, renal and hepatic function, pregnancy status, and the potential for zoonotic or trade-related consequences? The framework deliberately excludes specific milligram per kilogram doses, current formulary and label references must be consulted for dosing decisions.

A foundational distinction governs all antiviral reasoning. Viruses replicate intracellularly using host machinery, so antiviral drugs must enter cells and inhibit virus-specific enzymes or processes without arresting host cell function. The 90 approved antiviral drugs in human medicine cluster into 13 functional groups, including nucleoside analogues, protease inhibitors, neuraminidase inhibitors, and entry inhibitors, each targeting a defined viral protein or replication step as catalogued in the [review of approved antiviral drugs over the past 50 years](https://pubmed.ncbi.nlm.nih.gov/27281742/). Veterinary antiviral use draws from this same pharmacologic logic, though few of these compounds carry veterinary label indications. The clinician therefore reasons from mechanism and extrapolation, not from a comprehensive veterinary formulary.

## At a Glance

| Decision Parameter | Primary Consideration | Clinical Consequence |
|---|---|---|
| Virus family identification | Herpesviruses, retroviruses, influenza, coronaviruses | Determines which drug class can act |
| Replication strategy | DNA polymerase, reverse transcriptase, neuraminidase, protease | Drug target must match viral enzyme |
| Clinical syndrome | Ocular, respiratory, dermatologic, systemic | Tissue penetration and route of administration |
| Host immune status | Immunocompetent vs immunosuppressed | Duration of therapy and likelihood of resistance |
| Zoonotic potential | Rabies, influenza, SARS-CoV-2 | Public health reporting and infection control |
| Production setting | Companion vs food animal | Withdrawal periods and trade implications |
| Diagnostic confirmation | PCR, antigen detection, serology, cytology | Avoids unnecessary antiviral exposure |
| Drug toxicity profile | Nephrotoxicity, myelosuppression, teratogenicity | Monitoring parameters and contraindications |

## Viral Pathogenesis and the Logic of Antiviral Targeting

Antiviral drugs interrupt the viral life cycle at defined points: attachment, entry, uncoating, genome replication, protein synthesis, assembly, and release. The most clinically useful veterinary antivirals target genome replication. Nucleoside analogues such as acyclovir and its prodrug valacyclovir require phosphorylation by viral thymidine kinase before incorporation into viral DNA, where they terminate chain elongation. This explains their selectivity for herpesviruses and their relative safety in uninfected host cells. Pyrophosphate analogues such as foscarnet inhibit viral DNA polymerase directly without requiring viral kinase activation, which makes them useful against thymidine kinase-deficient resistant strains but also less selective and more toxic.

The distinction between DNA and RNA viruses determines drug availability. DNA viruses, particularly herpesviruses, have stable polymerases that are well-characterized drug targets. RNA viruses mutate more rapidly and their polymerases are error-prone, which complicates drug design and promotes resistance. Influenza neuraminidase inhibitors exploit a conserved enzymatic site on the viral surface, whereas coronavirus therapeutics have largely targeted proteases or polymerase complexes. The [Syrian hamster model for SARS-CoV-2 infection](https://pubmed.ncbi.nlm.nih.gov/32571934/) demonstrated that antiviral countermeasures can be evaluated in a small animal model with relevant lung pathology and that passive antibody transfer can suppress viral replication, illustrating the translational pathway from target identification to in vivo validation.

## Classifying the Clinical Problem

The first branch in the decision framework is syndromic. Ocular disease in cats, particularly conjunctivitis and keratitis, is overwhelmingly herpetic in origin and responds to topical or systemic nucleoside analogues. Upper respiratory disease in cats may involve feline herpesvirus-1, calicivirus, or both, and the antiviral strategy differs because calicivirus is an RNA virus without a reliable drug target. Dermatologic lesions in horses may reflect equine herpesvirus, papillomavirus, or poxvirus, each requiring a different therapeutic approach. Systemic febrile illness with lymphopenia in a cat should prompt consideration of feline infectious peritonitis, where antiviral therapy with protease inhibitors has shown promise but remains an area of active investigation instead of established practice.

Diagnostic confirmation precedes antiviral selection. PCR from conjunctival swabs, nasal swabs, or whole blood can identify the virus and, in some assays, quantify viral load. Cytology may reveal intranuclear inclusion bodies characteriztic of herpesvirus infection. Serology distinguishes prior exposure from active infection poorly in vaccinated animals and should not be used as the sole basis for antiviral initiation. The [MSD Veterinary Manual professional edition](https://www.msdvetmanual.com/) provides species-specific guidance on sample selection and interpretation for common veterinary viral pathogens.

## Host Factors That Modify Drug Selection

Hepatic and renal function determine drug clearance for most nucleoside analogues. Acyclovir and valacyclovir are renally excreted, and dose adjustment is required in animals with azotemia. Feline patients pose a particular challenge because their hepatic glucuronidation capacity is limited, and some antiviral drugs show prolonged half-lives compared with other species. Pregnancy status matters because several antiviral drugs are teratogenic or embryotoxic in animal models, and the risk-benefit calculation shifts when the dam and litter are both at risk.

Immune competence is the single most important host modifier. Immunosuppressed animals, whether from retroviral infection, chemotherapy, or endogenous disease, require longer courses of antiviral therapy and have higher rates of resistance emergence. Conversely, immunocompetent animals with self-limiting viral infections may not require antiviral therapy at all, because the host immune response will clear the infection within the natural course of disease. The decision to treat must therefore weigh the severity of clinical signs, the likelihood of complications, and the cost and adverse effect profile of the drug against the expected benefit of shortening the clinical course.

## Species-Specific Considerations and Extrapolation Limits

Companion animal antiviral therapy relies heavily on extrapolation from human pharmacology and from experimental infection models. The [Davis-Thompson Foundation veterinary pathology resources](https://www.davisthompsonfoundation.org/) offer case material that illustrates the gross and histopathologic lesions of viral diseases, which supports diagnostic reasoning when molecular testing is unavailable or pending. Production animal antiviral therapy is constrained by withdrawal periods, cost per animal, and the economics of treatment relative to culling. In food animals, the decision to treat a viral infection is often superseded by biosecurity protocols and depopulation strategies, particularly for highly contagious pathogens with trade implications as defined in the [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/).

Zoonotic viruses require a different decision calculus. Rabies is invariably fatal and antiviral therapy has no role, post-exposure prophylaxis and vaccination are the only interventions. Influenza viruses in animals may have pandemic potential, and treatment decisions may be guided by public health authorities instead of individual patient benefit. The [AVMA practice resources](https://www.avma.org/resources-tools) provide guidance on zoonotic disease management and professional obligations regarding reporting and infection control.

## Diagnostic Sequence for Antiviral Decision-Making

The clinical pathway begins with confirmation that a virus is the operative pathogen, also a coincidental finding. Polymerase chain reaction detects nucleic acid but cannot distinguish viable virus from residual genome fragments, so a positive result must be interpreted alongside cytology, histopathology, antigen testing, or virus isolation where available. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides species-specific guidance on which confirmatory tests carry diagnostic weight for each suspected virus.

Three questions structure the assessment. First, is the virus causing current disease or is it latent, subclinical, or a bystander? Second, does the clinical syndrome have a self-limiting course where supportive care alone is appropriate? Third, does an antiviral drug with proven efficacy against this virus exist, and can it be sourced and administered safely in this patient?

### Step 1: Establish the Viral Aetiology

Clinical signs alone rarely distinguish viral from bacterial, protozoal, or non-infectious causes. Feline upper respiratory signs, for example, can arise from feline herpesvirus type 1 (FHV-1), calicivirus, *Bordetella bronchiseptica*, *Chlamydia felis*, or *Mycoplasma* species. The decision to start an antiviral hinges on test results that implicate a specific virus, because nucleoside analogues active against herpesviruses have no activity against calicivirus.

Sample selection follows the suspected tissue tropism. Conjunctival and oropharyngeal swabs suit FHV-1 and calicivirus. Whole blood or buffy coat preparations suit feline leukemia virus (FeLV) antigen testing. Fecal samples suit canine parvovirus antigen assays. The [Davis-Thompson Foundation](https://www.davisthompsonfoundation.org/) pathology resources illustrate the histologic patterns that support viral aetiology when biopsy material is available, including intranuclear inclusion bodies in herpesvirus infection and syncytial cell formation in paramyxovirus infection.

### Step 2: Determine Whether Antiviral Therapy Will Change the Outcome

Antiviral drugs suppress viral replication but do not eliminate established viral nucleic acid from host cells. For acute lytic infections such as canine parvovirus, the window for meaningful antiviral intervention is narrow because viral replication peaks before clinical signs appear. For chronic infections such as FeLV, antiviral drugs may reduce viraemia but rarely achieve clearance. For latent infections such as FHV-1, antivirals suppress reactivation episodes but do not eradicate the latent viral reservoir in trigeminal ganglia.

The decision to treat therefore depends on whether the clinical course is compressible. Feline herpesvirus keratitis responds to topical antiviral therapy because corneal epithelial cells support active viral replication that can be suppressed. Feline infectious peritonitis, caused by a coronavirus, has historically resisted antiviral therapy, although newer protease inhibitors have shown promise in controlled studies. Where evidence is lacking, the clinician should state that uncertainty explicitly and discuss the expected benefit with the owner before committing to a drug course.

### Step 3: Match the Drug Class to the Virus

The approved antiviral drug repertoire, developed primarily for human medicine, organizes into functional groups that target specific viral enzymes or entry mechanisms. [De Clercq and Li's review of approved antiviral drugs](https://pubmed.ncbi.nlm.nih.gov/27281742/) catalogues 90 drugs in 13 functional groups, including nucleoside analogues, protease inhibitors, integrase inhibitors, and neuraminidase inhibitors. Veterinary use draws almost entirely from the nucleoside analogue and pyrophosphate analogue classes, with occasional use of protease inhibitors and interferons.

| Virus | Drug Class | Mechanism | Veterinary Use Context |
|-------|-----------|-----------|------------------------|
| FHV-1 | Acyclic guanosine analogues (famciclovir, aciclovir) | Viral thymidine kinase phosphorylates prodrug, triphosphate inhibits viral DNA polymerase | Systemic or topical, famciclovir preferred for oral dosing in cats |
| FHV-1 | Pyrophosphate analogue (foscarnet) | Non-competitive inhibition of viral DNA polymerase | Topical rescue therapy for aciclovir-resistant keratitis |
| FHV-1 | 5-substituted 2'-deoxyuridine analogues (idoxuridine, trifluridine) | Incorporation into viral DNA causes chain termination | Topical ophthalmic preparations |
| Canine herpesvirus | Acyclic guanosine analogues | As above | Neonatal puppies, limited efficacy once clinical signs develop |
| FeLV | Nucleoside reverse transcriptase inhibitors (zidovudine) | Chain termination of reverse transcription | Reduces viral load, does not clear infection |
| Influenza | Neuraminidase inhibitors (oseltamivir) | Blocks viral release from infected cells | Canine influenza, efficacy window is narrow |
| Parvovirus | None with proven efficacy | Not applicable | Supportive care remains primary |

## Decision Points That Change the Plan

### Acute Versus Chronic Presentation

Acute viral syndromes demand rapid therapeutic decisions. The clinician must ask whether the drug can be started within the viral replication window. For canine influenza, oseltamivir must begin within 48 hours of exposure or onset to meaningfully reduce shedding and clinical severity. After that window, the drug adds cost and potential gastrointestinal side effects without measurable benefit.

Chronic or recurrent syndromes allow a different calculus. Feline herpesvirus stomatitis or recurrent keratitis may warrant suppressive famciclovir during known stress periods, such as boarding or introduction of a new pet. The decision to use intermittent versus continuous therapy depends on episode frequency and severity, and the owner should understand that treatment suppresses episodes instead of curing the infection.

### Species and Production System Constraints

Drug selection changes with the species treated. Cats metabolise aciclovir poorly, achieving subtherapeutic plasma concentrations after oral dosing, which is why famciclovir is preferred. Dogs tolerate aciclovir better but still require higher doses than humans. Exotic species, including birds and reptiles, have sparse pharmacokinetic data for most antiviral drugs, and extrapolation from mammalian dosing is unreliable.

Production animal practice introduces withdrawal period and residue concerns that do not apply to companion animals. Antiviral drugs are rarely labelled for food animals, and extralabel use carries residue avoidance obligations. The [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) address disease control and trade implications for notifiable viral diseases, and the [AVMA practice resources](https://www.avma.org/resources-tools) provide guidance on extralabel drug use obligations in the United States. Clinicians in other jurisdictions must consult their local regulatory framework.

### Patient Status and Comorbidity

Hepatic and renal function determine drug clearance and toxicity risk. Famciclovir is converted to penciclovir, the active metabolite, with renal excretion, dose adjustment is required in azotaemic cats. Zidovudine causes bone marrow suppression, so hematologic monitoring is mandatory during therapy. Pregnant or lactating animals present additional risk, and the clinician should weigh the teratogenicity potential of nucleoside analogues against the consequences of untreated viral disease.

## Monitoring Parameters and What Each Detects

Monitoring serves two purposes: confirming drug efficacy and detecting toxicity. The monitoring schedule depends on the drug, the virus, and the patient's baseline organ function.

| Parameter | Frequency | What It Detects | Action Threshold |
|-----------|-----------|-----------------|------------------|
| Clinical sign score (ocular discharge, corneal ulceration, respiratory signs) | Every 3 to 7 days | Therapeutic response | No improvement after 7 days prompts re-evaluation of diagnosis or drug choice |
| Serum creatinine and urea | Baseline, then weekly for renally cleared drugs | Drug accumulation and nephrotoxicity | Rising creatinine above reference interval prompts dose reduction |
| Complete blood count | Baseline, then every 2 weeks for zidovudine | Bone marrow suppression | Anemia, leukopenia, or thrombocytopenia prompts dose reduction or discontinuation |
| Hepatic enzymes | Baseline, then monthly for prolonged therapy | Hepatotoxicity | Transaminase elevation above 2 times reference interval prompts investigation |
| Viral load (PCR or antigen) | Baseline and at end of therapy | Virologic response | Persistent viraemia may indicate resistance or inadequate dosing |

Clinical response remains the primary endpoint for most veterinary antiviral therapy. Laboratory monitoring detects toxicity but does not replace careful serial examination. For ocular disease, fluorescein staining documents corneal healing, and progression of ulceration while on therapy warrants reassessment of the diagnosis, consideration of bacterial superinfection, or a change in drug class.

## Documentation and Case Recording

The medical record should capture the diagnostic basis for antiviral selection, the drug and formulation chosen, the planned duration, and the monitoring schedule. Record the specific test that confirmed the viral aetiology, including the laboratory and assay type. Note any extralabel use status, because antiviral drugs are rarely labelled for veterinary species, and document that the owner received an explanation of expected benefits and potential adverse effects.

Serial examination findings should be recorded at each recheck, including objective measures such as corneal ulcer diameter, respiratory rate, or lesion size. Photographic documentation is valuable for ocular and dermatologic lesions because it permits objective comparison across visits. If therapy is changed, record the reason, whether lack of efficacy, adverse effects, or new diagnostic information.

The [Davis-Thompson Foundation](https://www.davisthompsonfoundation.org/) case material demonstrates how histopathologic documentation supports antiviral decision-making when biopsy is feasible. In practice, most antiviral decisions rest on clinical signs and molecular testing, and the record should reflect the level of diagnostic certainty achieved.

## When to Withdraw or Withhold Antiviral Therapy

Antiviral therapy should be withdrawn when the clinical syndrome resolves, when the drug fails to produce measurable improvement within a defined period, or when toxicity outweighs benefit. A 7 to 14 day trial is reasonable for most acute presentations, lack of response within that window should trigger diagnostic reassessment instead of dose escalation.

Withhold antiviral therapy when the virus is not the primary pathogen, when the infection is self-limiting and supportive care suffices, when the patient has contraindications such as severe renal or hepatic disease, or when the owner cannot commit to the monitoring schedule. The decision to withhold is as clinically important as the decision to treat, and it should be documented with the same care.

## Recognized Complications and Failure Modes

Antiviral therapy fails through several recognizable pathways. The most common is aetiological misclassification, where a bacterial, fungal, or non-infectious process is treated as viral. Early detection depends on the diagnostic sequence described previously: cytology, antigen testing, or molecular assays should precede drug initiation whenever the clinical presentation is ambiguous. A second failure mode is correct diagnosis but incorrect drug class selection. Nucleoside analogues targeting herpesvirus DNA polymerase have no activity against influenza neuraminidase, and vice versa. The functional grouping of approved antiviral drugs, as catalogued in the [review of approved antiviral drugs over the past 50 years](https://pubmed.ncbi.nlm.nih.gov/27281742/), provides a useful cross-check: each virus family maps to a limited set of mechanistically appropriate classes.

A third failure mode is dose or duration error. Subtherapeutic dosing suppresses viral replication incompletely and favours resistance, while premature discontinuation permits rebound. Monitoring parameters such as clinical score, viral load where available, and serial antigen testing detect these problems, but only if the monitoring interval matches the drug's pharmacodynamic profile. A fourth mode is host intolerance. Hepatotoxicity, nephrotoxicity, and bone marrow suppression are class-specific concerns that require baseline and serial laboratory assessment. The [MSD Veterinary Manual professional edition](https://www.msdvetmanual.com/) lists species-specific adverse effect profiles that should be reviewed before initiating therapy in an unfamiliar species.

| Observation | Likely cause | Discriminating check |
|---|---|---|
| No clinical response after 48 to 72 hours | Wrong aetiology, wrong drug class, or resistance | Repeat diagnostic testing, verify drug class matches virus family |
| Initial improvement then relapse | Premature discontinuation or resistance | Assess owner compliance, consider resistance testing if available |
| Rising liver or kidney values | Drug toxicity | Compare to baseline, review species-specific adverse effect profile |
| Worsening respiratory signs despite therapy | Secondary bacterial infection | Cytology, culture, or thoracic imaging |

## Common Errors and Corrective Action

Less experienced clinicians most often err by treating before diagnosis. The impulse to start a broad-spectrum antiviral "just in case" is understandable but unsupported: antiviral drugs are narrow-spectrum by design, and the [classification of approved antiviral drugs into 13 functional groups](https://pubmed.ncbi.nlm.nih.gov/27281742/) reflects this specificity. The corrective action is to commit to a diagnostic plan with a defined time frame before drug initiation, reserving empirical therapy for cases where diagnostic delay carries greater risk than treatment.

A second error is extrapolating human dosing and efficacy data to veterinary species without adjustment. Pharmacokinetics differ across species, and the [Syrian hamster model for SARS-CoV-2 countermeasure development](https://pubmed.ncbi.nlm.nih.gov/32571934/) illustrates how species-specific models are needed to evaluate antiviral efficacy before clinical application. The corrective action is to consult species-specific formularies and, where no veterinary data exist, to state that uncertainty explicitly in the medical record.

A third error is failing to revisit the diagnosis when therapy fails. Clinicians should ask whether the original diagnostic test was appropriate, whether sample quality was adequate, and whether the clinical course has changed the differential diagnosis. The [Davis-Thompson Foundation pathology resources](https://www.davisthompsonfoundation.org/) provide case material that can help clinicians recognize patterns of viral versus non-viral tissue injury when histopathology is available.

## Limitations of the Evidence Base

The veterinary antiviral evidence base is thin for most species and viruses. Much of what is prescribed in practice is extrapolated from human medicine, companion animal case series, or in vitro susceptibility data. Controlled trials are scarce, and comparative studies between drug classes are rarer still. Expert opinion differs on several points: whether antiviral therapy alters outcome in feline herpesvirus keratitis beyond symptomatic care, whether oseltamivir provides meaningful benefit in canine influenza, and whether combination therapy offers advantages over monotherapy in any veterinary viral disease.

Regulatory approval status also varies by region and species. Some antiviral drugs are approved for food animals in certain jurisdictions but not others, and withdrawal periods may differ accordingly. The [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) address disease control obligations that may influence treatment decisions in production animals, particularly for notifiable diseases where treatment is prohibited or discouraged. Clinicians should verify local requirements through their [national veterinary professional body](https://www.avma.org/resources-tools) before prescribing in these contexts.

## Referral, Consultation, and Reporting

Referral is warranted when the diagnosis is uncertain despite appropriate testing, when the patient deteriorates on therapy, when resistance is suspected and alternative agents are unfamiliar, or when the species falls outside the clinician's experience. Specialist consultation with a veterinary virologist, clinical pharmacologist, or ophthalmologist is appropriate for complex cases. Laboratory involvement is indicated for viral load monitoring, resistance genotyping, and histopathological confirmation where ante-mortem testing is inconclusive.

Regulatory reporting obligations arise when a notifiable viral disease is suspected or confirmed. Requirements differ by jurisdiction and species, and the [WOAH terrestrial animal health code](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) provides international standards for disease notification and trade implications. In production animal settings, treatment decisions may be secondary to herd-level control measures, including culling and movement restrictions. Clinicians should know which diseases are notifiable in their region before initiating antiviral therapy in food animals, because treatment can complicate surveillance and eradication programs.

## Frequently Asked Questions

### How do I choose an antiviral when cost limits the owner's options?

Prioritize by expected clinical impact instead of convenience. For acute, self-limiting viral infections where supportive care is the mainstay, antiviral cost is difficult to justify. For chronic infections such as feline herpesvirus, compare the cost of continuous antiviral therapy against episodic treatment triggered by clinical flares. Generic human formulations of acyclovir and famciclovir are often less expensive than veterinary-compounded products, but verify bioavailability in the target species before substituting. When the owner cannot afford the first-choice drug, select the agent with the most favourable efficacy-to-cost ratio for that specific virus, and document the financial constraint in the medical record. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides species-specific pharmacology guidance that supports these comparisons.

### What should I do when point-of-care viral testing is unavailable?

Proceed with treatment based on clinical pattern recognition, but state the diagnostic uncertainty explicitly in the record. For suspected feline herpesvirus keratitis, the characteriztic dendritic ulcer on fluorescein examination is sufficiently specific to justify empirical antiviral therapy. For systemic viral disease, cytology, histopathology, or hematology may support a viral aetiology without identifying the agent. When empirical therapy is initiated, choose a drug with a broad enough spectrum to cover the most likely pathogens, define a response deadline, and reassess at that point. The [Davis-Thompson Foundation](https://www.davisthompsonfoundation.org/) pathology resources offer case-based material that sharpens pattern recognition when laboratory confirmation is delayed.

### How does the decision framework change for exotic or non-domestic species?

Extrapolation from domestic species is the default but must be adjusted for metabolic differences. Many exotic species metabolise nucleoside analogues differently, and bioavailability data are sparse. For avian patients with herpesvirus infections, consult species-specific formularies and start at the lower end of published dose ranges while monitoring for adverse effects. For reptiles, temperature-dependent metabolism alters drug clearance, so environmental temperature must be stable before interpreting drug response. In food-producing exotic species, withdrawal periods are often undefined, which creates legal and ethical barriers to treatment. The [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) address trade and food safety implications that apply when treating production animals.

### What monitoring is realistic in a busy first-opinion practice?

Serial clinical scoring is the most practical monitoring tool. For feline herpesvirus, photograph corneal lesions at each recheck and document the frequency of sneezing episodes. For canine distemper, track neurological signs against a standardized checklist. Hematology and biochemistry are indicated when using drugs with known marrow or hepatic toxicity, but the frequency depends on the drug and the patient's baseline status. In practice, a recheck at 7 to 14 days after starting therapy captures most response failures. If the owner cannot return for rechecks, schedule a telephone consultation at the response deadline and instruct them to report specific signs, such as eye closure or appetite, instead of asking for a general status update.

### How should I document antiviral therapy decisions for medico-legal safety?

Record the suspected or confirmed viral aetiology, the drug selected, the rationale for that choice, and the response deadline. Note any off-label use, which is common for antiviral drugs in veterinary medicine, and confirm the owner understood this. Document the discussion of cost, expected benefit, and potential adverse effects. If you declined antiviral therapy, record the reasoning, particularly when the owner requested it. The [AVMA practice resources](https://www.avma.org/resources-tools) provide guidance on informed consent and medical record standards that apply to these decisions. Include photographs of lesions where feasible, as they provide objective evidence of response or progression.

### How do I explain to a client why antiviral therapy is not indicated?

Frame the explanation around the virus-host interaction instead of the drug. Explain that some viral infections are self-limiting and resolve with supportive care, while others require antiviral drugs to control replication. Use the analogy of a race between viral replication and the immune response, and explain that antiviral drugs only help when the virus is actively replicating and the drug can reach it. Be honest about uncertainty, including the possibility that the diagnosis is presumptive. Offer the monitoring plan as a concrete next step, and invite the owner to call if specific signs worsen. This approach preserves trust even when the owner expected a prescription.

## Related Clinical & Scientific Guides

* [Hypersensitivity Reactions: Types and Mechanisms](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/hypersensitivity-reactions-types-and-mechanisms)
* [Therapeutic Decision-Making for Respiratory Infections in Cattle](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/therapeutic-decision-making-respiratory-infections-cattle)
* [Monitoring Fluid Therapy in Critically Ill Veterinary Patients](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/monitoring-fluid-therapy-critically-ill-veterinary)


## References and Further Reading

- [Approved Antiviral Drugs over the Past 50 Years.](https://pubmed.ncbi.nlm.nih.gov/27281742/). 2016.
- [Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development.](https://pubmed.ncbi.nlm.nih.gov/32571934/). 2020.
- [Davis-Thompson Foundation Veterinary Pathology Resources](https://www.davisthompsonfoundation.org/). Davis-Thompson Foundation.
- [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual.
- [American Veterinary Medical Association Practice Resources](https://www.avma.org/resources-tools). American Veterinary Medical Association.
- [WOAH Terrestrial Animal Health Code](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/). WOAH.

## Related Articles

- [Decision Framework for Anticoagulant Therapy in Veterinary Patients](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/decision-framework-anticoagulant-therapy-veterinary)
- [Decision Framework for Antiemetic Therapy in Veterinary Patients](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/decision-framework-antiemetic-therapy-veterinary)
- [Decision Framework for Choosing Antifungal Therapy in Veterinary Patients](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/decision-framework-antifungal-therapy-veterinary)
- [Decision Framework for Antihypertensive Therapy in Veterinary Patients](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/decision-framework-antihypertensive-therapy-veterinary)
- [Decision Framework for Antiparasitic Therapy in Companion Animals](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/decision-framework-antiparasitic-therapy-companion-animals)

> This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.